HDAC Inhibitors

HDAC Inhibitors

Author: Scott Williams

Highly potent histone deacetylase (HDAC) inhibitors were developed by a team of researchers from academic, industry, and government settings, lead by Florian Thaler, European Institute of Oncology, Milan, Italy.

Because aberrant HDAC activity has been linked to several diseases including cancer, compounds that effect its specific blockade are heavily sought after. In an effort to improve the potency and pharmacokinetic (PK) profile of compounds that block HDAC activity, Thaler et al. used a novel amidopropenyl hydroxamic acid scaffold in their syntheses. Biological characterization showed that several of the resulting compounds show good in vitro potency and remarkably high microsomal stability. Their work also indicates that these compounds are catabolized by non-microsomal enzymes, as relatively high clearance rates were observed in in vivo PK studies.


Leave a Reply

Your email address will not be published.